Latest International Markets News

X2M Connect has secured $1.49 million in its second tranche placement and plans to issue additional options to investors, pending shareholder approval, to support its expanding smart city technology ambitions.

Recce Pharmaceuticals has signed a non-binding term sheet with a major Middle Eastern pharma player for exclusive rights to commercialise its R327 Topical Gel across the MENA region, targeting a high diabetes burden market.

ClearVue Technologies has inked a manufacturing and distribution agreement with Aria Glass Industries, marking a major step into India’s booming construction sector backed by a US$240 million investment.

AFT Pharmaceuticals posted a 22% revenue jump to NZ$254.7 million and a 39% increase in operating profit to a record NZ$24.4 million for FY26, exceeding guidance. The company targets over NZ$300 million revenue for FY27, fueled by international expansion and a deepening R&D pipeline.

RAS Technology Holdings has locked in new contracts and extensions expected to add at least $2 million in annualised revenue, reinforcing growth in wagering technology and international markets.

BCAL Diagnostics has embedded referral forms for its early cancer detection tests into clinical software used by 97% of Australian GPs, launched a telehealth platform, and opened a Sydney clinic, gearing up for a multi-cancer test launch in June 2026.

ALS Limited reported a 25.8% jump in underlying net profit after tax to AUD 381.2 million for FY26, driven by strong commodity testing demand and margin expansion. The company raised its dividend and advanced major hub lab projects while navigating a post-year-end cyber incident.

Vista Group International is set to roll out its Digital Enablement platform across 88 Cineworld cinemas in the UK during 2026, building on last year’s deployment at 25 Picturehouse sites.

Temple & Webster has delivered its most profitable April ever with EBITDA hitting around $2.5 million, setting the stage for a near doubling of earnings in FY27 despite weak consumer confidence.

Bioxyne has locked in a two-year, $50 million exclusive supply agreement with German pharmaceutical distributor ADREXpharma, granting exclusive rights to its Dr Watson® brand in Germany and reinforcing its foothold in Europe’s largest medicinal cannabis market.

Life360 surged to $143.1 million in Q1 2026 revenue, powered by 27% growth in paying subscribers and a 329% jump in advertising following the Nativo acquisition. The company raised its full-year guidance as it navigates temporary user growth headwinds.

Merino & Co. secures a significant AUD 1.1 million order from its China distribution partner, marking the first major commercial milestone under its exclusive China distribution agreement and signalling growing demand for its wool products.